Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.30 USD
Change Today +0.22 / 1.46%
Volume 310.2K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

ignyta inc (RXDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/15 - $19.40
52 Week Low
11/20/14 - $6.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IGNYTA INC (RXDX)

Related News

No related news articles were found.

ignyta inc (RXDX) Related Businessweek News

No Related Businessweek News Found

ignyta inc (RXDX) Details

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering or acquiring, developing, and commercializing new drugs for cancer patients. Its products pipeline consists of entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related and protein kinase. The company was founded in 2011 and is based in San Diego, California.

63 Employees
Last Reported Date: 05/11/15
Founded in 2011

ignyta inc (RXDX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $608.3K
Chief Financial Officer
Total Annual Compensation: $260.4K
Chief Operating Officer
Total Annual Compensation: $455.1K
Clinical and Regulatory Strategy Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

ignyta inc (RXDX) Key Developments

Ignyta, Inc. Announces Release for Clinical Use of Proprietary NGS Clinical Trial Assay to Support STARTRK Clinical Studies

Ignyta, Inc. announced the release for clinical use of its first clinical trial assay to support patient identification and enrollment into its STARTRK clinical development program for entrectinib. Entrectinib is the company’s proprietary oral tyrosine kinase inhibitor, targeting tumors that harbor activating alterations to NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1 or ALK. The NGS-based clinical trial assay will initially be performed only to identify potential patients for clinical trial enrollment and will not be offered for commercial use.

Ignyta, Inc.(NasdaqCM:RXDX) added to Russell 2000 Index

Ignyta, Inc. will be added to Russell 2000 Index

Ignyta, Inc.(NasdaqCM:RXDX) added to Russell 3000 Index

Ignyta, Inc. will be added to the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXDX:US $15.30 USD +0.22

RXDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXDX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RXDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,087.5x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,287.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IGNYTA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at